Heiko Konig, MD, PhD
Adjunct Clinical Associate Professor of Medicine
- Address
-
Walther Hall, R3-C312
HEMO
IN
Indianapolis, IN - PubMed:
-
| Year | Degree | Institution |
|---|---|---|
| 2014 | Fellowship | Johns Hopkins University School of Medicine |
| 2011 | Residency | St. Louis University School of Medicine |
| 2008 | Fellowship | City of Hope National Medical Center |
| 2005 | Residency | University of Mannheim Medical Center |
| 2002 | PhD | Philipps University of Marburg |
| 2000 | MD | University of Munich |
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; Shallis RM; Wei W; Montesinos P; Lengline E; Neukirchen J; Bhatt VR; Sekeres MA; Fathi AT; Konig H; Luger S; Khan I; Roboz GJ; Cluzeau T; Martínez-Cuadron D; Raffoux E; Germing U; Umakanthan JM; Mukherjee S; Brunner AM; Miller A; McMahon CM; Ritchie EK; Rodríguez-Veiga R; Itzykson R; Boluda B; Rabian F; Tormo M; Acuña-Cruz E; Rabinovich E; Yoo B; Cano I; Podoltsev NA; Bewersdorf JP; Gore S; Zeidan AM; Leukemia 2020 Mar 4
Stahl M; Shallis RM; Wei W; Montesinos P; Lengline E; Neukirchen J; Bhatt VR; Sekeres MA; Fathi AT; Konig H; Luger S; Khan I; Roboz GJ; Cluzeau T; Martínez-Cuadron D; Raffoux E; Germing U; Umakanthan JM; Mukherjee S; Brunner AM; Miller A; McMahon CM; Ritchie EK; Rodríguez-Veiga R; Itzykson R; Boluda B; Rabian F; Tormo M; Acuña-Cruz E; Rabinovich E; Yoo B; Cano I; Podoltsev NA; Bewersdorf JP; Gore S; Zeidan AM; Leukemia 2020 Mar 4
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
Shallis RM; Stahl M; Wei W; Montesinos P; Lengline E; Neukirchen J; Bhatt VR; Sekeres MA; Fathi AT; Konig H; Luger S; Khan I; Roboz GJ; Cluzeau T; Martínez-Cuadron D; Raffoux E; Germing U; Umakanthan JM; Mukhereje S; Brunner AM; Miller A; McMahon CM; Ritchie EK; Rodríguez-Veiga R; Itzykson R; Boluda B; Rabian F; Tormo M; Acuña-Cruz E; Rabinovich E; Yoo B; Cano I; Podoltsev NA; Bewersdorf JP; Gore S; Zeidan AM; Leukemia & lymphoma 2020 Feb 26
Shallis RM; Stahl M; Wei W; Montesinos P; Lengline E; Neukirchen J; Bhatt VR; Sekeres MA; Fathi AT; Konig H; Luger S; Khan I; Roboz GJ; Cluzeau T; Martínez-Cuadron D; Raffoux E; Germing U; Umakanthan JM; Mukhereje S; Brunner AM; Miller A; McMahon CM; Ritchie EK; Rodríguez-Veiga R; Itzykson R; Boluda B; Rabian F; Tormo M; Acuña-Cruz E; Rabinovich E; Yoo B; Cano I; Podoltsev NA; Bewersdorf JP; Gore S; Zeidan AM; Leukemia & lymphoma 2020 Feb 26
A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Christian S; Arain S; Patel P; Khan I; Calip GS; Agrawal V; Sweiss K; Griffin S; Cahill K; Konig H; Esen A; Shergill A; Odenike O; Stock W; Quigley JG; American journal of hematology 2020 Apr 20
Christian S; Arain S; Patel P; Khan I; Calip GS; Agrawal V; Sweiss K; Griffin S; Cahill K; Konig H; Esen A; Shergill A; Odenike O; Stock W; Quigley JG; American journal of hematology 2020 Apr 20
The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H; Journal of cellular and molecular medicine 2018 Jan 12
Brinda B; Khan I; Parkin B; Konig H; Journal of cellular and molecular medicine 2018 Jan 12
Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
Sayar H; Cripe LD; Saliba AN; Abu Zaid M; Konig H; Boswell HS; Leukemia research 2018 Dec 24
Sayar H; Cripe LD; Saliba AN; Abu Zaid M; Konig H; Boswell HS; Leukemia research 2018 Dec 24
Enzyme-immobilized hydrogels to create hypoxia for in vitro cancer cell culture.
Dawes CS; Konig H; Lin CC; Journal of biotechnology 2017 Mar 8
Dawes CS; Konig H; Lin CC; Journal of biotechnology 2017 Mar 8
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.
Gbolahan OB; Zeidan AM; Stahl M; Abu Zaid M; Farag S; Paczesny S; Konig H; International journal of molecular sciences 2017 Jul 31
Gbolahan OB; Zeidan AM; Stahl M; Abu Zaid M; Farag S; Paczesny S; Konig H; International journal of molecular sciences 2017 Jul 31
Consecutive epigenetically-active agent combinations act in <i>ID1-RUNX3-TET2</i> and <i>HOXA</i> pathways for <i>Flt3ITD+ve</i> AML.
Sayar H; Liu Y; Gao R; Zaid MA; Cripe LD; Weisenbach J; Sargent KJ; Nassiri M; Li L; Konig H; Suvannasankha A; Pan F; Shanmugam R; Goswami C; Kapur R; Xu M; Boswell HS; Oncotarget 2017 Dec 25
Sayar H; Liu Y; Gao R; Zaid MA; Cripe LD; Weisenbach J; Sargent KJ; Nassiri M; Li L; Konig H; Suvannasankha A; Pan F; Shanmugam R; Goswami C; Kapur R; Xu M; Boswell HS; Oncotarget 2017 Dec 25
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK; Blood 2016 Nov 21
Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK; Blood 2016 Nov 21
Treatment of Acute Myeloid Leukemia in Elderly Patients-A Therapeutic Dilemma.
Mamdani H; Santos CD; Konig H; Journal of the American Medical Directors Association 2016 Apr 9
Mamdani H; Santos CD; Konig H; Journal of the American Medical Directors Association 2016 Apr 9
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H; Leukemia 2015 Dec 21
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H; Leukemia 2015 Dec 21
Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.
Konig H; Santos CD; Current cancer drug targets 2015
Konig H; Santos CD; Current cancer drug targets 2015
Targeting FLT3 to treat leukemia.
Konig H; Levis M; Expert opinion on therapeutic targets 2014 Sep 18
Konig H; Levis M; Expert opinion on therapeutic targets 2014 Sep 18
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Sehgal AR; Konig H; Johnson DE; Tang D; Amaravadi RK; Boyiadzis M; Lotze MT; Leukemia 2014 Nov 26
Sehgal AR; Konig H; Johnson DE; Tang D; Amaravadi RK; Boyiadzis M; Lotze MT; Leukemia 2014 Nov 26
Is targeted therapy feasible in acute myelogenous leukemia?
Konig H; Levis M; Current hematologic malignancy reports 2014 Jun
Konig H; Levis M; Current hematologic malignancy reports 2014 Jun
Pilot study of erlotinib in patients with acute myeloid leukemia.
Sayar H; Czader M; Amin C; Cangany M; Konig H; Cripe LD; Leukemia research 2014 Dec 2
Sayar H; Czader M; Amin C; Cangany M; Konig H; Cripe LD; Leukemia research 2014 Dec 2
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH; EMBO molecular medicine 2013 Jan 22
Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH; EMBO molecular medicine 2013 Jan 22
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
Nam S; Scuto A; Yang F; Chen W; Park S; Yoo HS; Konig H; Bhatia R; Cheng X; Merz KH; Eisenbrand G; Jove R; Molecular oncology 2012 Feb 17
Nam S; Scuto A; Yang F; Chen W; Park S; Yoo HS; Konig H; Bhatia R; Cheng X; Merz KH; Eisenbrand G; Jove R; Molecular oncology 2012 Feb 17
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A; Haematologica 2008 Mar 26
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A; Haematologica 2008 Mar 26
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
Konig H; Holtz M; Modi H; Manley P; Holyoake TL; Forman SJ; Bhatia R; Leukemia 2008 Feb 14
Konig H; Holtz M; Modi H; Manley P; Holyoake TL; Forman SJ; Bhatia R; Leukemia 2008 Feb 14
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R; Cancer research 2008 Dec 1
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R; Cancer research 2008 Dec 1
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P; Haematologica 2007 Jun
Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P; Haematologica 2007 Jun
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
Müller MC; Saglio G; Lin F; Pfeifer H; Press RD; Tubbs RR; Paschka P; Gottardi E; O'Brien SG; Ottmann OG; Stockinger H; Wieczorek L; Merx K; König H; Schwindel U; Hehlmann R; Hochhaus A; Haematologica 2007 Jul
Müller MC; Saglio G; Lin F; Pfeifer H; Press RD; Tubbs RR; Paschka P; Gottardi E; O'Brien SG; Ottmann OG; Stockinger H; Wieczorek L; Merx K; König H; Schwindel U; Hehlmann R; Hochhaus A; Haematologica 2007 Jul
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Konig H; Holyoake TL; Bhatia R; Blood 2007 Dec 4
Konig H; Holyoake TL; Bhatia R; Blood 2007 Dec 4
Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
Verbeek W; König H; Boehm J; Kohl D; Lange C; Heuer T; Scheibenbogen C; Reis HE; Hochhaus A; Graeven U; Acta haematologica 2006
Verbeek W; König H; Boehm J; Kohl D; Lange C; Heuer T; Scheibenbogen C; Reis HE; Hochhaus A; Graeven U; Acta haematologica 2006
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A; Leukemia 2003 Sep
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A; Leukemia 2003 Sep
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A; Leukemia 2003 Dec
Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A; Leukemia 2003 Dec
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.